dokumendiregister.ee
OtsingAsutusedMCP
Otsing›Sotsiaalministeerium
Sissetulev kiriAvalik

International Herbal Pharmacopoeia

Sotsiaalministeerium · 11. november 2020
Viit
1.4-2/3243-1
Registreeritud
11. november 2020
Dokumendi liik
Sissetulev kiri
Adressaat
WHO
Saabumis/saatmisviis
e-post
Funktsioon
1.4 EL otsustusprotsess ja rahvusvaheline koostöö
Sari
1.4-2 Rahvusvahelise koostöö korraldamisega seotud kirjavahetus (Arhiiviväärtuslik)
Toimik
1.4-2/2020
Vastutaja
Elen Ohov (Sotsiaalministeerium, Kantsleri vastutusvaldkond, Euroopa Liidu ja väliskoostöö osakond)

Failid

  • 📎E-kiri.pdf78 KB
  • 📎EST_Letter_nomination.pdf137 KB
  • 📎Expert Committee (ECIHP) provisional selection criteria.pdf252 KB
  • 📎Key points of draft outline of IHP with timelines.pdf186 KB

Sisu (failidest)

WORLD HEALTH ORGANIZATION ORGANISATION MONDIALE DE LA SANTÉ WELTGESUNDHEITSORGANISATION Date: 4 November 2020 ВСЕМИРНАЯ ОРГАНИЗАЦИЯ ЗДРАВООХРАНЕНИЯ REGIONAL OFFICE FOR EUROPE Ms Elen Ohov BUREAU RÉGIONAL DE L’EUROPE REGIONALBÜRO FÜR EUROPA Adviser ЕВРОПЕЙСКОЕ РЕГИОНАЛЬНОЕ БЮРО European Union Affairs and International Co- Head office: operation Department UN City, Marmorvej 51, Ministry of Social Affairs DK-2100 Copenhagen Ø, Denmark Suur-Ameerika 1 Tel.: +45 45 33 70 00; Fax: +45 45 33 70 01 Email: [email protected] Tallinn 10122 Website: http://www.euro.who.int Estonia Email: [email protected] Dear Ms Ohov, International Herbal Pharmacopoeia (IHP) A growing international market for and increasing applications of herbs/herbal products have raised concerns about the safety, quality and effectiveness of such products. Increasingly, Member States have expressed to WHO the need to develop an International Herbal Pharmacopoeia (IHP) to address these concerns. The objectives of the IHP are to: a) formulate an international pharmacopoeial standard by adapting and harmonizing selected monographic entries from existing national/regional pharmacopoeias including herbs/herbal products (NPHs) or national herbal pharmacopoeias (NHPs) of different Member States, as well as constructing de novo entries that will be recognized and accepted as a standard for promoting standardization of herbs/herbal products; b) contribute to ensuring the safety and quality of herbs/herbal products in the global market; and c) serve as a reference for Member States which do not have an NHP or Herbal National Pharmacopoeia (HNP), so that they may formulate their standards or adopt the IHP as a formal safety and quality standard of herbs/herbal products, thereby strengthening the technical support by WHO to the Member States. As the first formal step in developing the IHP, WHO headquarters and the WHO Regional Office for Europe would like to begin by creating an Expert Committee in consultation and agreement with the Member States. In this regard, we seek your support in recommending experts for the Committee. The suggested candidates will be further screened and selected by the IHP Secretariat following relevant rules and principles. If you are in agreement with this proposal, we would appreciate if you could kindly let us know the details (name, job title, e-mail address, etc.) of the 2–5 experts you wish to nominate; for Member States that have existing national guidelines about the use of herbs/herbal products, a minimum of five and a maximum of seven experts can be nominated. Please send your nomination(s) at your earliest convenience by email to Dr Olexandr Polishchuk, Technical Officer at the Regional Office, at [email protected], copying [email protected]. Should you have questions or need any further information, please do not hesitate to contact us. Yours faithfully, Dr Natasha Azzopardi Muscat Director Division of Country Health Policies and Systems UN City, Marmorvej 51 Tel.: +45 45 33 70 00 Email: [email protected] DK-2100 Copenhagen Ø Fax: +45 45 33 70 01 Website: http://www.euro.who.int Denmark Enclosures: Key points of draft outline of IHP with timelines Expert Committee (ECIHP) provisional selection criteria Copy for information to: Ms Triin Uusberg, Head, European and International Coordination Department, Ministry of Social Affairs, Suur-Ameerika 1, Tallinn 10129, Estonia, Email: [email protected], [email protected] H.E. Ms Katrin Saarsalu-Layachi, Ambassador Extraordinary and Plenipotentiary, Permanent Representative, Permanent Mission of the Republic of Estonia to the United Nations Office and other international organizations in Geneva, Chemin du Petit-Saconnex 28A, Genève CH-1209, Switzerland, Email: [email protected] H.E. Mr William Mart Laanemäe, Ambassador Extraordinary and Plenipotentiary, agréé, Embassy of the Republic of Estonia, Frederiksgade 19, 4th floor, Copenhagen K 1265, Denmark, Email: [email protected] Ms Kristina Köhler, Liaison Officer, WHO Country Office, Estonia, Paldiski Road 81, Tallinn 10617, Estonia, Email: [email protected] –2– 29 Sept.2020 Outline of the WHO International Herbal Pharmacopoeia (IHP) (Draft key points) 1. Background A growing international market and increasing applications of herbs/herbal products have raised concerns about the safety, quality and effectiveness of herbs/herbal products. To address these concerns more and more Member States have expressed to the World Health Organization (WHO) the need to develop an International Herbal Pharmacopoeia (IHP). These concerns arise mainly under three circumstances: (1) According to WHO Global Report on Traditional and Complementary Medicine 2019 and relevant data, the majority of countries where traditional medicine has been recognized in use by the national health authority do not have their own national pharmacopoeias including herbs/herbal products (NPHs)/ national herbal pharmacopoeias (NHPs) due to lack of capacity for the establishment of herbal standards. In such a case, some countries would adopt other countries’ NPHs/NHPs; while some other countries may not have any reference point for quality aspects of herbal medicines. (2) The import and export trade of herbs/herbal products can result in uncertain variances when traded from the original country to the international market and subsequently may cause potential problems in safety and quality. (3) The discrepancies in NPHs/NHPs of different countries may allow for significant differences in safety and quality of the same herbal product. These NPHs/NHPs are also difficult to adapt to cater for various quality requirements of herbal products unanimously recognized by different countries in the international market. The development of the IHP is aligned with WHO objectives, including: (1) The WHO Traditional Medicine Strategy 2014-2023: “to strengthen quality assurance, safety, proper use and effectiveness of traditional and complementary medicine (T&CM) by regulating T&CM products, practices and practitioners”(Strategic objective 2 of the strategy). (2) WHA resolution on traditional medicine(WHA67.18): “to continue to provide policy guidance to Member States on how to integrate traditional and complementary medicine services within their national and/or subnational health care system(s), as well as the technical guidance that would ensure the safety, quality and effectiveness of such traditional and complementary medicine services with an emphasis on quality assurance”. (3) WHO’s Thirteenth General Program of Work 2019-2023 (GPW13): “achieve the ‘triple-billion’ goal of GPW13 to ensure healthy lives and promote well-being for all”. (4) Constitution of WHO forty-fifth edition, 2006, article 2: “to develop, establish and promote international standards with respect to food, biological, pharmaceutical and similar products”. There is either no or insufficient information in specified current WHO technical documents concerning quality control for herbs/herbal products particularly pertaining to the requirements and specifications for the determination of chemical substances. Monographs as a result also lack adoption for legal recognitions while a greater focus on specified herbs/herbal products covering worldwide use is needed. (1) WHO International Pharmacopoeia (IP) ninth edition 2019 1 29 Sept.2020 (2) WHO technical guidelines or guidance related to efficacy and safety of herbal medicines: a. WHO Research Guidelines for Evaluating the Safety and Efficacy of Herbal Medicines 1993. b. WHO Monographs on Selected Medicinal Plants (Vol. 1-4, (1999, 2004, 2007,-2009) c. WHO Guidelines on Good Agricultural and Collection Practices (GACP) for Medicinal Plants 2003. d. WHO Guidelines on Good Manufacturing Practices (GMP) for Herbal Medicines 2007. e. WHO Guidelines for Assessing Quality of Herbal Medicines with Reference to Contaminants and Residues 2007. f. WHO Monographs on Selected Medicinal Plants Commonly Used in the Newly Independent States (NIS), 2010. g. WHO Quality Control Methods for Herbal Materials 2011. h. WHO Guidelines for Selecting Marker Substances of Herbal Origin for Quality Control of Herbal Medicines 2017. i. WHO Guidelines on Good Herbal Processing Practices for Herbal Medicines 2018. The development of an IHP faces the following challenges: (1) The quality and quantity of herbs/herbal products can vary from batch to batch due to intrinsic and extrinsic factors. Therefore, their quality standards may require the allowance for appropriate reference ranges and adaptability that would have regard for such acceptable variances (2) The discrepancies appearing in monographs for the same herbal substances in existing national pharmacopoeias may cause difficulties in harmonization for the development of the IHP. (3) To avoid the potential bias of inclusion of various herbs, criteria for selection of herbs for inclusion in the IHP may need to be developed. a. . The advantages for WHO to develop the IHP: The International Regulatory Cooperation for Herbal Medicines (IRCH) became a WHO network in 2017, providing a platform to facilitate and strengthen cooperation between the Member States with herbal regulations in sharing experiences, information and knowledge related to regulatory frameworks for governing the quality of herbal medicines. Thus, the WHO-IRCH network may provide a critical platform for supporting the development and maintenance of the IHP. It is part of the mission of WHO to provide technical support to the Member States in ensuring the safety and quality of herbs/herbal products in the international market and to help those countries who do not have their national pharmacopoeias in domestic quality control in herbs/herbal products by establishing the International Herbal Pharmacopoeia. Global standardization on herbs/herbal products is not only desired by governmental regulators, but also by manufacturers, international traders, and transnational consumers. Due to the lack of international resources and integration of these resources standardization of this field through the cooperation of member states or private business may be slow. WHO coordinates rich technical resources in traditional and complementary medicines and has networks of multiple WHO collaborating centers and expert advisory panel members on traditional medicine across the world. The WHO is therefore well-positioned to take the initiative to develop the IHP to promote the global standardization on herbs/herbal products and benefit all stakeholders. The actions planned to address the challenges in the development of WHO IHP: (1) The WHO IHP will keep the objective and function similar to the existing WHO IP in the same framework of WHO according to its own feasibility. The WHO IHP will primarily derive its monographs from national pharmacopoeias while seeking harmonization of the same 2 29 Sept.2020 monographs from different national pharmacopoeias. Meanwhile, WHO will also take into consideration the geographic needs in terms of the monograph’s requirements in indigenous herbs and the different levels of test methods that may be required due to differing availability of human, technical, and laboratory equipment and associated resources among the Member States. This will contribute to the goal of achieving maximum utilization of the IHP. (2) The development of the IHP will take advantage of the IRCH network platform in conducting some necessary activities but would not be limited to the IRCH members. This is because 125 Member States have established a registration system for herbal medicines but only 36 Member States have currently joined the IRCH network as of 2019. (3) The IHP will not be confined within the scope of herbal medicines but will extend to herbs/herbal products of non-medicines as well. This is because there is a need to integrate the potential value of all herbs associated with all herbal products and to appreciate the legal, regulatory and social differences currently occurring in across different countries. (4) Establish an expert committee for the IHP, its working groups and a steering group. (5) To eliminate any unwanted bis of selection, establish the criteria for correctly identifying herbs/herbal products for inclusion in the IHP. These criteria will include the regulatory status of the herb/herbal product, the intended use or application of the herb/herbal product including the frequency and extent of therapeutic usage, traditional importance of the herb/herbal product, national/regional needs, degree of international demand, international trade (import/export) data, and geographic distribution. The list for inclusion in the IHP will be consulted by the ECIHP across the six WHO regions. (6) Select WHO collaborating laboratories for drafting/verifying monographs and/or general test/analytical methods in the IHP across the six regions. (7) Select WHO laboratory centers of reference standards required in the IHP. 2. Objective The objectives of the IHP are to: a. formulate an international pharmacopoeial standard by adapting and harmonizing selected monographic entries from existing NPHs/NHPs of different member states, as well as construction of de novo entries that will be recognized and accepted as a standard for promoting standardization of herbs/herbal products; b. contribute to ensuring the safety and quality of herbs/herbal products in the global market; and c. serve as a reference for Member States, which do not have a National Herbal Pharmacopoeia (NHP) or Herbal National Pharmacopoeia (HNP), to formulate their own standards or for adoption of the IHP as a formal safety and quality standard of herbs/herbal products, thereby strengthening the technical support of the WHO to Member States. One of the missions of WHO Traditional, Complementary and Integrative Medicine (TCI) is to support the development and finalization of the IHP through the WHO IHP Secretariat, which it will establish. 3. Outcome The expected outcome of the IHP is: • Publications of the WHO International Herbal Pharmacopoeia (IHP) in three separated parts or volumes, consisting of herbs/herbal materials, herbal preparations, and finished herbal products, respectively. 3 29 Sept.2020 • The monographs in the WHO IHP formed through the harmonization of selected entries in the NPHs/NHPs of different countries will be used for the promotion of global standardization on herbs/herbal products. 4. Process 4.1 Expert committee for the IHP (ECIHP), working groups (WGs), steering group (SG) and activities 4.2 Scope and function of the WHO IHP 4.3 Criteria for identifying herbs/herbal products for inclusion in the list for the IHP 4.4 The list of herbs/herbal products for the WHO IHP 4.5 Proposed contents and development of the WHO IHP 4.5.1 Acknowledgements 4.5.2 Preface 4.5.3 Background 4.5.4 Introduction of the IHP 4.5.5 General notices 4.5.6 Appendices to the general notices 4.5.7 Monographs 4.5.7.1 Monographs for herbs/herbal materials 4.5.7.2 Monographs for herbal preparations 4.5.7.3 Monographs for finished herbal products 4.5.8 General chapters 4.5.8.1 Dosage Forms 4.5.8.2 General test/analytical methods 4.5.8.3 Reagents, test solutions and volumetric solutions, indicators 4.5.8.4 Markers and reference standards 4.6 Harmonization of monographs from national pharmacopoeias for the WHO IHP 4.7 Conditions for verification and validation on monographs in the WHO IHP 4 29 Sept.2020 5. Project implementation and timeline The proposal will be implemented in three phases over a period of 5 years. Gantt chart Timeline Year 1 Year 2 Year 3 Year 4 Year 5 Activities 1 2 3 4 5 6 7 8 9 10 Phase I: Draft the outline and set up the project drafting and preparation Set up a WHO ECIHP including its SG and WGs Establish the concrete list for inclusion in the IHP of herbs/herbal materials/herbal preparations/finished herbal products Select WHO collaborating laboratories for drafting/verifying monographs and/or general test/analytical methods in the IHP Phase II: Select WHO laboratory centers compiling the of reference standards required in WHO IHP the IHP Develop general chapters and monographs Global review of the WHO IHP Phase III: Publishing work publishing the WHO IHP 5 Saatja: LINDHARDT, Lisbeth Sjaelborg <[email protected]> Saadetud: 11.11.2020 13:09 Adressaat: Elen Ohov <[email protected]> Koopia: Triin Uusberg <[email protected]>; SM Info <[email protected]>; <[email protected]>; <[email protected]>; <[email protected]>; <[email protected]>; KÖHLER, Kristina <[email protected]> Teema: EST International Herbal Pharmacopoeia (IHP) Tähtsus: Kõrgeim &nbsp; Please see the attached correspondence sent from the World Health Organization, Regional Office for Europe. One or more attachments may be included.Mit der Bitte um Kenntnisnahme der beiliegenden Korrespondenz (eine oder mehrere Anlagen), Weltgesundheitsorganisation, Regionalb¨¹ro f¨¹r Europa. Veuillez vous r¨¦f¨¦rer ¨¤ la correspondance ci-jointe du Bureau r¨¦gional de l'Europe de l'Organisation mondiale de la sant¨¦. Une ou plusieurs annexes peuvent ¨ºtre jointes. §³§Þ. §á§â§Ú§Ü§â§Ö§á§Ý§Ö§ß§ß§à§Ö §á§Ú§ã§î§Þ§à §à§ä §¦§Ó§â§à§á§Ö§Û§ã§Ü§à§Ô§à §â§Ö§Ô§Ú§à§ß§Ñ§Ý§î§ß§à§Ô§à §Ò§ð§â§à §£§ã§Ö§Þ§Ú§â§ß§à§Û §à§â§Ô§Ñ§ß§Ú§Ù§Ñ§è§Ú§Ú §Ù§Õ§â§Ñ§Ó§à§à§ç§â§Ñ§ß§Ö§ß§Ú§ñ (§à§Õ§Ú§ß §Ú§Ý§Ú §ß§Ö§ã§Ü§à§Ý§î§Ü§à §á§â§Ú§Ü§â§Ö§á§Ý§Ö§ß§ß§í§ç §æ§Ñ§Û§Ý§à§Ó). &nbsp; &nbsp; Best regards, &nbsp; Lisbeth Lindhardt Health Technologies and Pharmaceuticals Programme WHO Regional Office for Europe &nbsp; Office 1.2.07 Ext 7 6764 &nbsp; HTP annual report 2019: &nbsp; Provisional selection criteria and process for members of the Expert Committee for the International Herbal Pharmacopoeia (ECIHP) 1. The International Herbal Pharmacopoeia (IHP) The objectives of the IHP are to: a. formulate an international pharmacopoeial standard by adapting and harmonizing selected monographic entries from existing NPHs/NHPs of different member states, as well as construction of de novo entries that will be recognized and accepted as a standard for promoting standardization of herbs/herbal products; b. contribute to ensuring the safety and quality of herbs/herbal products in the global market; and c. serve as a reference for Member States, which do not have a National Herbal Pharmacopoeia (NHP) or Herbal National Pharmacopoeia (HNP), to formulate their own standards or for adoption of the IHP as a formal safety and quality standard of herbs/herbal products, thereby strengthening the technical support of the WHO to Member States. One of the missions of the WHO Traditional, Complementary and Integrative Medicine (TCI) is to support the development and finalization of the IHP through the WHO IHP secretariat, which it will establish. 2. Expert Committee for the International Herbal Pharmacopoeia (ECIHP) The development of the IHP will be based on advice and recommendations from the Expert Committee for the International Herbal Pharmacopoeia (ECIHP) in line with rules and processes determined by the WHO. The inclusion of any herb or herbal product into the IHP remains the final decision of the WHO IHP secretariat based on the advice and recommendations made by the ECIHP. 2.1 Structure 2.1.1 The ECIHP will consist of three working groups (WGs), including: a. Herbs/herbal materials group (WG1); b. Herbal extracts/preparations group (WG2); and c. Finished herbal products group (WG3). 2.1.2 Each WG will consist of 10-15 members appointed by the WHO IHP secretariat. 2.1.3 Each WG will consist of two group leaders appointed by the WHO IHP secretariat. 2.1.4 In addition to the WGs stated in item 2.1.1, any ad hoc sub-group may be appointed for a temporary duration by the WHO IHP secretariat for limited, specific and immediate purposes such as editorial review of documents before their submission to the WHO IHP secretariat. 2.1.5 A steering group (SG) will be established as an executive body of the ECIHP members who will be selected from the three WGs by the WHO IHP secretariat. 2.1.6 The WHO IHP secretariat will appoint a chair and two co-chairs of the ECIHP who will also chair the SG. Selection Criteria and process for Members of Expert Committee for the International Herbal Pharmacopoeia (ECIHP) 2.2 Composition 2.2.1 Members of the ECIHP will be selected primarily from countries across the six WHO regions, where— a. herbs/herbal products are popularly used; and b. the national/regional pharmacopoeias including herbs/herbal products (NPHs) or national herbal pharmacopoeias (NHPs) are relatively well developed. 2.2.2 ECIHP members should possess expertise and extensive experience in pharmacopeia review, drafting and/or applications in terms of herbs/herbal products. 2.2.3 Notwithstanding 2.2.1, ECIHP members may be selected from the rosters of, the WHO Expert Advisory Panel on traditional medicine, WHO TCI collaborating centers, WHO IRCH, or from other relevant organizations or institutions, including national/regional regulatory agencies, national/regional pharmacopoeia commissions/committees, national administration of traditional medicines, academic institutions and associations, among others. 2.3 Objectives and Tasks 2.3.1 The three WGs are expected to make recommendations related to the most appropriate methods and procedures for the establishment of relevant IHP content including monographs, general notices, general chapters for general test/analytical methods, dosage form descriptions and necessary appendices. 2.3.2 The tasks of WG members will include, but not be limited to: a. Reviewing and reporting any advice or recommendations regarding any inclusions to the IHP; b. Periodically reviewing, discussing and commenting on the protocols of monographs and general test/analytical methods in the IHP completed by laboratories and institutions; c. Developing general notices and general chapters for dosage forms as well as populating appendices where required (e.g. lists of reagents, markers used in the monographs) in the IHP; d. Supplementing and finalizing the list of herbs/herbal materials, herbal preparations and herbal finished products, the list of general test/analytical methods, identified by WHO IHP secretariat; and e. Attendance of meetings including teleconferences as may be required. 2.3.3 WG members who are participating in laboratory research may draft monograph(s) or general test/analytical methods as per WHO IHP technical guidelines. These members will be requested to agree not to comment on their draft documents or any other documents from the same laboratory in writing or WG meetings. 2.3.4 WG members from WHO laboratory centers of reference standards will be responsible for the coordination of relevant laboratory centers, the WHO IHP secretariat and other stakeholders to ensure the timely availability and distribution of the reference standards being used in the development of the IHP. 2.3.5 WG leaders are responsible for the coordination within the individual group, and for coordinating the joint meetings or interactions with the SG and/or other WGs when necessary. 2.4 Duration of appointment 2.4.1 The first session of the ECIHP will last for two years. 2.4.2 Subsequent ECIHP sessions will renew every three years. 2.4.3 Applications for membership of the ECIHP will be requested by the WHO IHP secretariat for each session of the ECIHP as may be necessary. Page 2 of 6 Selection Criteria and process for Members of Expert Committee for the International Herbal Pharmacopoeia (ECIHP) 2.4.4 The first session of the ECIHP will draw on members from applications received by the WHO IHP secretariat. 2.4.5 With respect to subsequent ECIHP sessions the WHO IHP secretariat may — a. reappoint members from previous sessions based on satisfactory performance in the previous sessions and need of the WHO IHP secretariat; and b. appoint additional members as a result of any new application made in terms of paragraph 2.4.3. 3. Members of the ECIHP Membership criteria as well as the application and selection process is prescribed by the WHO IHP secretariat. 3.1 Criteria for Membership 3.1.1 ECIHP members should possess the expertise and extensive experience associated with pharmacopeia review and development and/or related applications in terms of herbs/herbal products. 3.1.2 The members of the ECIHP are required to have at least 10 years’ work experience in the disciplines related to herbal pharmacopoeia standards or herbal quality standards such as botany, pharmacognosy, phytochemistry, analytical chemistry, molecular biology, herbal material processing or phytopharmaceutical manufacturing. 3.1.3 Herbal professionals are expected to hold a senior title or position with the requisite experience demonstrable in their CVs. 3.1.4 The following candidates will be prioritized for consideration and appointment as members of the ECIHP: a. Experts from the WHO Expert Advisory Panel on traditional medicine or WHO TCI collaborating centers, who are familiar with pharmacopoeia and herbal quality standards; b. Members in the current session of national/regional pharmacopoeia commission/committee with respect to herbs/herbal products; and c. Experts who have made significant contributions to national/regional pharmacopoeias in terms of herbs/herbal products or herbal quality. 3.2 Application for Membership 3.2.1 Announcements for applications for ECIHP membership, including application forms and relevant guidelines, will be— a. placed online on the WHO TCI website; b. notified to all six WHO regional offices by the WHO IHP secretariat at least 30 days prior to each session of ECIHP membership; and c. notified to the relevant national organizations or institutions in item 2.2.3 by WHO country offices. 3.2.2 Unless otherwise expressly indicated by the WHO IHP secretariat in writing, only applications received before the stated deadline for the respective ECIHP session will be considered. Page 3 of 6 Selection Criteria and process for Members of Expert Committee for the International Herbal Pharmacopoeia (ECIHP) 3.2.3 Individuals may apply for ECIHP membership by way of one of the following ways: a. Governmental recommendation Membership candidates may be proposed by a national/regional governmental agency associated with the development or maintenance of pharmacopoeia or associated standards such as a drug regulatory agency, traditional medicine administration agency, national/regional pharmacopoeia body covering traditional medicines or national/regional traditional medicinal pharmacopoeia body. Members who were proposed by their national/regional governmental agencies shall be considered as representing their countries/regions on the ECIHP. b. Voluntary individual application Membership candidates may personally express interest in becoming the members of the ECIHP by way of voluntary application and submission of required supporting materials to the WHO IHP secretariat. Members who have applied by way of voluntary individual applications shall be considered to represent their own expert opinions and not those of their countries/regions when expressed on the ECIHP. c. WHO Invitation The WHO IHP secretariat may identify suitably qualified candidates and nominate such individuals for membership of the ECIHP following consensus reached with relevant stakeholders and partners. Membership candidates identified in terms of item 3.3.1 will be formally notified in writing thereof and invited to submit the relevant application documents as determined by the WHO IHP secretariat. 3.2.4 All applications for ECIHP membership must include: a. a cover letter or evidence of nomination/request where relevant; b. the WHO application form (Annex 1); c. the candidate’s CV/biosketch (Annex 2); and d. any other required form or information as may be required by the WHO. 3.3 Appointment of members 3.3.1 The appointment of an ECIHP member by the WHO IHP secretariat is subject to the review of the application materials received and relevant selection criteria as determined by the WHO following the WHO normal protocols/procedures. 3.3.2 The WHO IHP secretariat shall collect and review all application materials submitted and develop an ECIHP member candidate shortlist. 3.3.3 The WHO IHP secretariat shall select and appoint three members of the ECIHP who, subject to their acceptance, shall be designated as the chair and co-chairs of the ECIHP and SG. 3.3.4 After consultation with the chair and co-chairs, the WHO IHP secretariat will proceed to appoint all remaining members of the ECHIP from across the six WHO regions and to select members of the steering group (SG). 4. Public Statement of ECIHP Members/Activities Names and relevant designations of ECIHP members, as well as any meetings and official final documents of the ECIHP, may be published on the WHO website, WHO IRCH platforms or related WHO communications. Page 4 of 6 Selection Criteria and process for Members of Expert Committee for the International Herbal Pharmacopoeia (ECIHP) ANNEX 1 Application form for applying for the members of the ECIHP Last Name: First Name(s): Title: Sex: M F Age: Nationality: Occupation: Organization Organization name: address: Professional field(s): Current position(s): Email address: Telephone: Select one group within ECIHP for which you wish to apply (select one – see 2.1.1): WG1 WG2 WG 3 Briefly elaborate/tell why you would be best suited to this WG: Select a second group within ECIHP for which you wish to apply (optional – see 2.1.1): WG1 WG2 WG3 Briefly elaborate/tell why you would be best suited to this WG: Your type application for the ECIHP is (select one - see 3.2.3): Governmental Individual: WHO invitation recommendation: Supply a letter from the recommending Supply cover letter detailing suitability Supply evidence of the WHO invitation: institution indicating the name of the for appointment to ECIHP. organization and contact name and details of the person completing the recommendation or nomination and their authorization to do so. Page 5 of 6 Selection Criteria and process for Members of Expert Committee for the International Herbal Pharmacopoeia (ECIHP) ANNEX 2 CV Template All CVs submitted should consist of the following items in the preferred order as stated. Names SURNAMES (Title) MALE/FEMALE AGE NATIONALITY Provide detail of any nationality, citizenship(s) or residence status. 1. SUMMARY STATEMENT Maximum 25 words 2. CONTACT DETAILS Complete Physical Address Telephone Numbers Email Address 3. LIST OF ACADEMIC QUALIFICATIONS List applicable higher degrees and relevant certificates or diplomas by YEAR OBTAINED, NAME OF DEGREE, INSTITUTION 4. PROFESSIONAL APPOINTMENTS List professional appointments or experience by YEAR, POSITION, ORGANIZATION 5. PROFESSIONAL ACTIVITIES List professional activities by YEAR, ACTIVITY, ORGANIZATION 6. LIST OF PUBLICATIONS List publications by category: a) Dissertations, b) Articles, c) Books, d) Book Chapters 7. AWARDS Optional: list by YEAR, AWARD, ORGANIZATION Page 6 of 6
Allikas: Sotsiaalministeerium dokumendiregister →
dokumendiregister.eeAsutusedEesti avalike dokumendiregistrite otsing · nimistu.ee andmetel